A Post Marketing Surveillance Study of INVOSSA K Inj.

Post Marketing Surveillance on Safety and Effectiveness Evaluation of INVOSSA K Inj.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03412864

Enrollment

3000

Registered

2018-01-29

Start date

2017-07-12

Completion date

2023-07-11

Last updated

2019-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

chondrocyte cells, osteoarthritis, gene therapy

Brief summary

This study is post-marketing surveillance of Invossa K injection in patients with osteoarthritis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female patients over 19 years 2. Patients who diagnosed with osteoarthritis will plan to INVOSSA K Inj. injection and suitable for following criteria : \- Moderate knee osteoarthritis (Kellgren & Lawrence grade 3) with persistent symptoms (pain, etc.) in spite of conservative therapy (medication, physical therapy, etc.) for more than 3 months 3. Patients (or substitute) who is provided all information regarding participation of this PMS signed the informed consent form

Exclusion criteria

1. Pregnant or breastfeeding female 2. Patients who have administered corticosteroid before INVOSSA K Inj. injection within the past 30 days 3. Patients who have severe disease such as heart, liver, kidney disease or other severe complications 4. Patients who rheumatoid arthritis, gouty arthritis, autoimmune disease associated arthritis except for osteoarthritis 5. Patients with a medical history of allergic diseases or patients with a medical history of anaphylactic reactions (including patients with a history of hypersensitivity reactions to the components of this drug, including dimethylsulfoxide (DMSO), mannitol, dextran 40 or bovine proteins) 6. Patients who have been treated with injections to the target knee within the past three months or patients with a past history of surgery, including arthroscope, within the past six months 7. Patients currently with leukemia or malignant tumors such as osteochondroma, chondroblastoma, cartilaginous mucinous fibrous tumor, chondroma and chondrosarcoma, which may be exacerbated by administration of INVOSSA-K inj. or patients with a history thereof 8. Patients with Kellgran & Lawrence grade 4 osteoarthritis

Design outcomes

Primary

Measure	Time frame	Description
AEs (Adverse Events)	0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)	Changes of incidence rate in AEs

Secondary

Measure	Time frame	Description
100 mm VAS (Visual Analog Scale)	0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)	Changes of 100 mm VAS at each visit (Scale : 0\ 100, 0 : No pain, 100 : Worst imaginable pain)
Physical examination (Knee joint swelling)	0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)	Changes of Knee joint swelling at each visit
Physical examination (Tenderness)	0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)	Changes of tenderness at each visit
Physical examination (ROM)	0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)	Changes of ROM(Range Of Motion) at each visit
General efficacy evaluation	6 Months(visit 3)	General efficacy evaluation was assessed by following 4 criteria. (Improved, Not changed, Worsened, Unassessable)

Countries

South Korea

Outcome results